Penny stock biotech Synthetic Biologics sees its 'breakthrough' status pulled as FDA ponders safety issues
A little under a year ago the penny stock of Synthetic Biologics $SYN gyrated higher on the news that its drug SYN-004 (ribaxamase) — designed to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
